Real-world study of Il-23 inhibitors for inflammatory bowel disease
Part of Digestive system clinical trials.
This study is gathering information on how well Il-23 inhibitors work and how safe they are for people with ulcerative colitis or Crohn's disease in China. It is a real-world study, meaning it looks at people using these drugs in everyday medical practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with ulcerative colitis or Crohn's disease.
- Your doctor has decided it is time for you to start an il-23 inhibitor for the first time.
- You are not currently in or planning to join any other clinical trial.
- You do not have any medical reason that would make taking an il-23 inhibitor unsafe for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibody drug (IL-23 inhibitor) for people with Crohn's disease or ulcerative colitis. It aims to see if the drug is safe and effective. You may be able to join if you have moderate to severe disease and have not had certain bowel surgeries or infections.
This study follows patients with moderate-to-severe Crohn's disease who are starting a newer type of biologic medication called IL-23 inhibitors (guselkumab or risankizumab). Researchers want to understand how well these drugs work in real-world clinical practice and compare their effectiveness to other treatments.
This study tracks how well guselkumab (a biologic medication that blocks IL-23, a protein that drives inflammation) works for moderate-to-severe ulcerative colitis or Crohn's disease in everyday clinical practice. Researchers want to understand long-term benefits and safety in real patients.
This trial uses special fluorescent versions of adalimumab and risankizumab to see inflammation in the bowel during an endoscopic procedure. It may help find out which treatment works best for each person's inflammation.
This study looks at blood and/or tissue “molecular” (cell-level) reasons why treatments don’t fully work in adults with Crohn’s disease or ulcerative colitis. If you are starting a biologic or small-molecule medicine and still have moderate to severe symptoms, you may be able to contribute to research that helps improve future care.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
Hear when a new Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.